ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03193190
Recruitment Status : Recruiting
First Posted : June 20, 2017
Last Update Posted : November 16, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.


Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Drug: Nab-Paclitaxel Drug: Gemcitabine Drug: Oxaliplatin Drug: Leucovorin Drug: Fluorouracil Drug: Atezolizumab Drug: Cobimetinib Drug: PEGPH20 Drug: BL-8040 Drug: Selicrelumab Drug: Bevacizumab Drug: Emactuzumab Drug: RO6874281 Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 205 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Actual Study Start Date : July 5, 2017
Estimated Primary Completion Date : November 16, 2019
Estimated Study Completion Date : September 19, 2020

Arm Intervention/treatment
Active Comparator: Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)

Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.

Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria.

Drug: Nab-Paclitaxel
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

Drug: Gemcitabine
Gemcitabine will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab
Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1−4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
Drug: Nab-Paclitaxel
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

Drug: Gemcitabine
Gemcitabine will be administered as per the schedule specified in the respective arm.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: Selicrelumab
Selicrelumab will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 1: Atezolizumab + Chemo + Selicrelumab + Bevacizumab
Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous on Day 1 of Cycles 1−4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
Drug: Nab-Paclitaxel
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

Drug: Gemcitabine
Gemcitabine will be administered as per the schedule specified in the respective arm.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: Selicrelumab
Selicrelumab will be administered as per the schedule specified in the respective arm.

Drug: Bevacizumab
Bevacizumab will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab
Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Drug: Nab-Paclitaxel
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

Drug: Gemcitabine
Gemcitabine will be administered as per the schedule specified in the respective arm.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: Bevacizumab
Bevacizumab will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 1: Atezolizumab + Chemotherapy + Emactuzumab
Cohort 1: Participants will receive Emactuzumab 1000 mg IV infusion on Days 1 and 15 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Drug: Nab-Paclitaxel
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

Drug: Gemcitabine
Gemcitabine will be administered as per the schedule specified in the respective arm.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: Emactuzumab
Emactuzumab will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 2: Atezolizumab + Cobimetinib

Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.

Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: Cobimetinib
Cobimetinib will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 2: Atezolizumab + PEGPH20

Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: PEGPH20
PEGPH20 will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 2: Atezolizumab + BL-8040

Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.

Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: BL-8040
BL-8040 will be administered as per the schedule specified in the respective arm.

Experimental: Cohort 2: Atezolizumab + RO6874281 every 2 weeks

Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.

Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: RO6874281
RO6874281 will be administered as per the schedule specified in the respective arm

Experimental: Cohort 2: Atezolizumab + RO6874281 every 3 weeks

Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.

Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: RO6874281
RO6874281 will be administered as per the schedule specified in the respective arm

Experimental: Cohort 2: Atezolizumab + Emactuzumab

Cohort 2: Participants will receive Emactuzumab 1000 mg IV infusion on day 1 of each 21 day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.

Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: Emactuzumab
Emactuzumab will be administered as per the schedule specified in the respective arm.

Active Comparator: Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)

Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.

Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment.

Drug: Nab-Paclitaxel
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

Drug: Gemcitabine
Gemcitabine will be administered as per the schedule specified in the respective arm.

Drug: Oxaliplatin
Oxaliplatin will be administered as per the schedule specified in the respective arm.

Drug: Leucovorin
Leucovorin will be administered as per the schedule specified in the respective arm.

Drug: Fluorouracil
Fluorouracil will be administered as per the schedule specified in the respective arm.




Primary Outcome Measures :
  1. Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) [ Time Frame: From randomization until disease progression or loss of clinical benefit (up to approximately 3-5 years) ]
  2. Percentage of Participants With Adverse Events (AEs) [ Time Frame: From first study treatment administration until 30 days after the last dose or until initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 3-5 years) ]

Secondary Outcome Measures :
  1. Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1 [ Time Frame: From randomization up to the first occurrence of disease (up to approximately 3-5 years) ]
  2. Overall Survival [ Time Frame: From randomization up to death from any cause (up to approximately 3-5 years) ]
  3. Percentage of Participants who are Alive at Month 6 [ Time Frame: Month 6 ]
  4. Duration of Response, as Determined by Investigator According to RECIST v1.1 [ Time Frame: From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years) ]
  5. Percentage of Participants With Disease Control, as Determined by Investigator According to RECIST v1.1 [ Time Frame: From randomization until disease progression or loss of clinical benefit (up to approximately 3-5 years) ]
  6. Serum Concentration of Atezolizumab [ Time Frame: Pre-infusion (0 hour [hr]) on Day 1 of Cycle 1 up to 30 days and 120 days after last dose (up to approximately 3-5 years)(Detailed timeframe is provided in outcome measure description) ]
    Pre-infusion (0 hour [hr]), 30 minutes (min) post-infusion (infusion duration=60 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Day 1 of Cycles 2, 3, 4, 8, 12, 16 (21 or 28 day cycles); 30 days and 120 days after last dose (up to approximately 3-5 years)

  7. Plasma Concentration of Cobimetinib [ Time Frame: Pre-dose (0 hr) and 2-4 hrs post-dose on Day 15 of Cycle 1 (cycle length=28 days)(up to approximately 3-5 years). ]
  8. Plasma Concentration of PEGPH20 [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycle 1 up to 30 days and 120 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description) ]
    Pre-infusion (0 hr), 5 min and 1-3 hrs post infusion (infusion duration=10-12 min) on Day 1 of Cycle 1; pre-infusion (0 hr) on Days 8 and 15 of Cycle 1, and Day 1 of Cycles 3, 4, 8, 12, 16; pre-infusion (0 hr) and 5 min post-infusion on Day 1 of Cycle 2 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-5 years)

  9. Plasma Concentration of BL-8040 [ Time Frame: Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description) ]
    Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1); 1 hr post-dose on Days 1, 5 of priming period; pre-dose (0 hr), 1 hour post-dose on Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16; pre-dose (0 hr) on Day 1 of Cycle 20 and every 4 cycles thereafter (each cycle=21 days); 30 days after last dose (up to approximately 3-5 years).

  10. Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (21 or 28 day cycles); 30 days and 120 days after last dose (up to approximately 3-5 years) ]
  11. Percentage of Participants With ADA to PEGPH20 [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 (each cycle=21 days); 30 days and 120 days after last dose (up to approximately 3-5 years) ]
  12. Percentage of Participants With ADA to BL-8040 [ Time Frame: Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Day 1 of Cycle 1) up to 30 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description) ]
    Pre-dose (0 hr) on Day 1 of priming period (1 week prior to Cycle 1 Day 1), Day 15 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 8, 12, 16, 20 and every 4 cycles thereafter (each cycle=21 days) (up to approximately 3-5 years); 30 days after last dose (up to approximately 3-5 years)

  13. Serum Concentration of RO6874281 [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycle 1 up to 30 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description) ]

    For RO6874281 Q2W: Pre-infusion (0 hour [hr]), at end of infusion, and 4 hours after infusion on Day 1 of Cycle 1; pre-infusion (0 hr) and at end of infusion on Day 15 of Cycle 1; pre-infusion (0 hr) and at end of infusion on day 1 of Cycles 2, 3, 4, 6, 8, 10, 12, 15 and 18 and every third cycle thereafter (each cycle=28 days); and 30 days after last dose (up to approximately 3-5 years).

    For RO6874281 Q3W: Pre-infusion (0 hour [hr]), at end of infusion, 2 hours after infusion and 4 hours after infusion on Day 1 of Cycles 1 and 3; 24 hours after the Day 1 infusion for Cycles 1 and 3; 48 hours after the Day 1 infusion for Cycles 1 and 3; 168 hours after the Day 1 infusion for Cycles 1 and 3; 1 hour after initiation of infusion on Day 1 of Cycle 1; pre-infusion (0 hr) and at end of infusion on day 1 of Cycles 2, 4, 6, 8, 10, 12, 14, 16 and 19 and every third cycle thereafter (each cycle=21 days); and 30 days after last dose (up to approximately 3-5 years).


  14. Serum Concentration of Emactuzumab [ Time Frame: Pre-dose (0 hour [hr]) on Day 1 of Cycle 1 up to 30 days after last dose (up to approximately 3-5 years)(Detailed timeframe is provided in outcome measure description) ]

    Cohort 1: Pre-dose (0 hour [hr]) on Day 1 and 8 of Cycle 1; pre-dose (0 hr) and at end of Emactuzumab infusion on day 1 of Cycles 2, 3, 4, 8, 12 and 16 (each cycle = 28 days); and 30 days after last dose (up to approximately 3-5 years).

    Cohort 2: Pre-dose (0 hour [hr]) on Day 1 of Cycle 1; on Day 15 of Cycle 1; pre-dose (0 hr) and at end of Emactuzumab infusion on day 1 of Cycles 2, 3, 4, 8, 12 and 16 (each cycle = 21 days); and 30 days after last dose (up to approximately 3-5 years).


  15. Serum Concentration of Selicrelumab [ Time Frame: Pre-dose (0 hour [hr]) on Days 1 and 8 of Cycle 1, 4, 8, 12 and 16; pre-dose (0 hr) on day 1 of Cycle 2 (each cycle = 28 days); and 30 days after last dose (up to approximately 3-5 years). ]
  16. Serum Concentration of Bevacizumab [ Time Frame: Pre-dose (0 hour [hr]) on Days 1 of Cycle 1 and 4 (each cycle = 28 days); and 30 days after last dose (up to approximately 3-5 years). ]
  17. Percentage of Participants With ADA to RO6874281 [ Time Frame: Pre-infusion (0 hr) on Day 1 of Cycle 1 up to 30 days after last dose (up to approximately 3-5 years) (Detailed timeframe is provided in outcome measure description). ]

    RO6874281 Q2W arm: Pre-infusion (0 hour [hr]) on Days 1 and 15 of Cycle 1; pre-infusion (0 hour [hr]) on Day 1 of Cycles 2, 3, 4, 6, 8, 10, 12, 15 and 18 and every third cycle thereafter (each cycle=28 days); and 30 days after last dose (up to approximately 3-5 years).

    RO6874281 Q3W arm: Pre-infusion (0 hour [hr]) on Day 1 of cycles 1, 2, 3, 4, 6, 8, 10, 12, 14, 16 and 19 and every third cycle thereafter (each cycle=21 days); and 30 days after last dose (up to approximately 3-5 years).


  18. Percentage of Participants With ADA to Emactuzumab [ Time Frame: Pre-dose (0 hour [hr]) on Day 1 up to 30 days after last dose (up to approximately 3-5 years)(Detailed timeframe is provided in outcome measure description). ]

    Cohort 1: Pre-dose (0 hour [hr]) on Day 1 and 8 of Cycle 1; pre-dose (0 hr) on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (each cycle = 28 days); and 30 days after last dose (up to approximately 3-5 years).

    Cohort 2: Pre-dose (0 hour [hr]) on Day 1 of Cycle 1; on Day 15 of Cycle 1; pre-dose (0 hr) on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (each cycle = 21 days); and 30 days after last dose (up to approximately 3-5 years).


  19. Percentage of Participants With ADA to Selicrelumab [ Time Frame: Pre-dose (0 hour [hr]) on Day 1 of cycles 1, 2, 4, 8, 12 and 16 (each cycle = 28 days); and 30 days after last dose (up to approximately 3-5 years). ]
  20. Percentage of Participants With ADA to Bevacizumab [ Time Frame: Pre-dose (0 hour [hr]) on Day 1 of Cycles 1 and 4 (each cycle = 28 days); and 30 days after last dose (up to approximately 3-5 years). ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma
  • For patients in Cohort 1: no prior systemic treatment for PDAC
  • For patients in Cohort 2: disease progression during administration of either 5-FU− or gemcitabine-based first-line chemotherapy
  • Life expectancy greater than or equal to 3 months
  • Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing
  • Measurable disease (at least one target lesion) according to RECIST v1.1
  • Adequate hematologic and end-organ function test results
  • Tumor accessible for biopsy
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm

Exclusion Criteria:

  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • History of leptomeningeal disease
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Positive human immunodeficiency (HIV) test at screening or at any time prior to screening
  • Active hepatitis B or C virus infection or active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Prior allogeneic stem cell or solid organ transplantation
  • History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03193190


Contacts
Contact: Reference Study ID Number: WO39608 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

  Show 25 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03193190     History of Changes
Other Study ID Numbers: WO39608
2016-004126-42 ( EudraCT Number )
First Posted: June 20, 2017    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Paclitaxel
Gemcitabine
Oxaliplatin
Atezolizumab
Albumin-Bound Paclitaxel
Bevacizumab
Fluorouracil
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents